Opus Genetics (IRD) Research & Development (2010 - 2026)
Opus Genetics (IRD) reported Research & Development of $10.6 million for Q1 2026, up 32.99% year-over-year from $8.0 million in Q1 2025, and up 1.43% quarter-over-quarter from $10.4 million in Q4 2025.
Opus Genetics (IRD) Research & Development (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Research & Development data on file, last reported at $10.6 million in Q1 2026.
- Research & Development for Q1 2026 came in at $10.6 million, up 32.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.4 million (up 11.25% YoY), and the FY2025 annual result was $30.8 million, up 14.75% from the prior year.
- Research & Development rose to $10.6 million in Q1 2026 per IRD's latest filing, from $10.4 million in the prior quarter.
- Over five years, Research & Development peaked at $10.6 million in Q1 2026 and troughed at $2.8 million in Q3 2022.
- A 5-year average of $5.9 million and a median of $5.6 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development soared 157.07% in 2024, then decreased 28.65% in 2025.
- A 5-year view of Research & Development shows it stood at $3.6 million in 2022, then grew by 7.11% to $3.8 million in 2023, then surged by 83.13% to $7.0 million in 2024, then jumped by 48.25% to $10.4 million in 2025, then increased by 1.43% to $10.6 million in 2026.
- Business Quant data shows IRD's Research & Development at $10.6 million in Q1 2026, $10.4 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | 10.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.58 Mn |
| Dec 31, 2025 | 10.43 Mn |
| Sep 30, 2025 | 6.41 Mn |
| Jun 30, 2025 | 6.02 Mn |
| Mar 31, 2025 | 7.95 Mn |
| Dec 31, 2024 | 7.03 Mn |
| Sep 30, 2024 | 8.98 Mn |
| Jun 30, 2024 | 6.09 Mn |
| Mar 31, 2024 | 4.75 Mn |
| Dec 31, 2023 | 3.84 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Jun 30, 2023 | 4.72 Mn |
| Mar 31, 2023 | 5.60 Mn |
| Dec 31, 2022 | 3.59 Mn |
| Sep 30, 2022 | 2.84 Mn |
| Jun 30, 2022 | 3.16 Mn |
| Mar 31, 2022 | 4.77 Mn |
| Dec 31, 2021 | 4.74 Mn |
| Sep 30, 2021 | 3.13 Mn |
| Jun 30, 2021 | 3.83 Mn |